文献速递消化道肿瘤与早癌消化内镜

两基因甲基化DNA生物标志物检测联合非内镜球囊在高风险筛查人群中检测巴雷特食管

Use of a Two-Gene Methylated DNA Biomarker Assay and Nonendoscopic Balloon for Detection of Barrett Esophagus Among High-Risk Individuals in a Screening Population.
PubMed 文献 · Am J Gastroenterol · 2024-11-26

前瞻性多中心研究评估EsoGuard检测联合EsoCheck装置在符合ACG指南标准的高风险人群中检测巴雷特食管(BE)的性能与安全性。93例纳入主要分析,BE检出8例(8.6%),敏感性87.5%(95%CI 47.4-99.7),特异性81.2%(95%CI 71.2-88.8),无严重不良事件。作者认为该非内镜方法在高风险患者中安全、准确且耐受良好,但需进一步研究精确界定其性能特征。

要点

  • EG/EC在符合ACG指南标准的高风险人群中检测BE的敏感性为87.5%,特异性为81.2%。
  • 轻度食管擦伤发生率1.5%,未报告严重不良事件。
  • 作者认为EG/EC在高风险患者中是有前景的非内镜筛查替代方法。

核心结论

  • 在符合ACG指南标准的预期使用人群中,EG/EC用于BE筛查似乎有前景;该方法可能为高风险患者提供安全、准确且耐受良好的非内镜替代选择。
  • 作者指出,未来需要进一步研究以更精确地界定其性能特征。

研究设计与样本

  • 前瞻性、多中心研究(NCT04293458),在美国和西班牙24个中心开展。
  • 纳入年龄>50岁、有慢性胃食管反流病且符合ACG指南标准(慢性GERD及3项以上额外危险因素)的男性受试者180例,其中163例(90.6%)完成EGD并成功实施EC。
  • 主要终点为EG检测BE和EAC的性能,以EGD及活检为对照;EC安全性和可用性为次要终点。

主要发现

  • 主要分析人群93例中,8例(8.6%)经EGD检出BE,均无异型增生。
  • EG检测BE的敏感性为87.5%(95%CI 47.4-99.7),特异性为81.2%(95%CI 71.2-88.8),阳性预测值为30.4%(95%CI 13.2-52.9),阴性预测值为98.6%(95%CI 92.3-99.96)。
  • 轻度食管擦伤发生率为1.5%;未报告严重不良事件。
  • 受试者平均年龄60.5岁,34.4%为肥胖,56.7%有吸烟史,3.9%有一级亲属BE或EAC史。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出,未来需要进一步研究以更精确地界定EG/EC的性能特征。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Barrett esophagus (BE) is the precursor to esophageal adenocarcinoma (EAC). We aimed to assess performance, safety, and tolerability of the EsoGuard (EG) assay on samples collected nonendoscopically with the EsoCheck (EC) device (EG/EC) for BE detection in the intended-use population meeting American College of Gastroenterology guideline criteria (chronic gastroesophageal reflux disease and 3+ additional risk factors). METHODS: We performed a prospective, multicenter study (NCT04293458) to assess EG performance (primary endpoint) on cells collected with EC, for detection of BE and EAC using esophagogastroduodenoscopy (EGD) and biopsies as the comparator. Twenty-four sites across the United States and Spain participated. EC safety and usability were assessed as secondary endpoints. RESULTS: 180 male subjects aged >50 years with chronic gastroesophageal reflux disease met eligibility criteria, of which 163 (90.6%) had EGD and successful EC administration. Mean age was 60.5 years, 34.4% were obese, 56.7% had tobacco history, and 3.9% had a 1st degree relative with BE or EAC. Of 122 samples analyzed, 93 contributed to the primary endpoint analysis. Eight subjects (8.6%) in the Primary Analysis Population had BE on EGD, none with dysplasia. Sensitivity of EG for BE was 87.5% (95% confidence interval [CI] 47.4-99.7), specificity was 81.2% (95% CI 71.2-88.8), positive predictive value was 30.4% (95% CI 13.2-52.9), and negative predictive value was 98.6% (95% CI 92.3-99.96). Mild esophageal abrasions were observed in 1.5%; no serious adverse events were reported. DISCUSSION: This study in the intended-use population suggests that EG/EC is promising for BE screening. While future work is necessary to define its performance characteristics with more precision, this approach may provide a safe, accurate, and well-tolerated nonendoscopic alternative in high-risk patients.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Shaheen NJ, Othman MO, Taunk J, et al. Use of a Two-Gene Methylated DNA Biomarker Assay and Nonendoscopic Balloon for Detection of Barrett Esophagus Among High-Risk Individuals in a Screening Population. Am J Gastroenterol. 2024. PMID: 39588974. doi:10.14309/ajg.0000000000003238

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。